Loading...
Loading...
Mylan Inc.
MYL today
announced that it has entered into an agreement with Pfizer
PFE for the exclusive
worldwide rights to develop, manufacture and commercialize Pfizer's generic
equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus
incorporating Pfizer's proprietary dry powder inhaler delivery platform.
Advair® Diskus and Seretide® Diskus are inhaled fixed-dose combinations of
Fluticasone Propionate and Salmeterol delivered via a dry powder inhaler and
are used to treat asthma and COPD.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in